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This study was initiated to evaluate the in vivo infectivity and pathogenicity of a group of recombinant feline leukemia
viruses (rFeLVs) previously generated by in vitro forced recombination between a FeLV subgroup A virus (FeLV-A) and an
endogenous FeLV (enFeLV) envelope (env) element (Sheets et al., 1992, Virology 190, 849–855). To determine infectivity of
rFeLVs, neonatal cats were inoculated with rFeLVs alone or in combination with FeLV-A. The recombinant viruses were
able to replicate efficiently in vivo only when administered along with FeLV-A. Of six co-infected cats, three developed
thymic lymphosarcomas, one severe aplastic anemia, and two cachexia and depression; all were viremic and seroconverted
shortly after inoculation. While both virus types were detected in virtually all tissues examined from these tumor-bearing
cats, there was a particularly noteworthy sequence reversion in the rFeLVs. It is known that exogenous FeLV isolates carry
a conserved neutralizing MGPNL epitope in the middle of the surface glycoprotein domain of the env gene. In contrast, the
parental recombinant viruses used to inoculate these cats harbored the enFeLV-derived MGPNP sequence at this position.
However, all in vivo-propagated recombinants displayed the MGPNL sequence, while the env-encoded backbone flanking
the MGPNL sequence was that of the parental recombinant virus. These results suggest that viruses with the MGPNL
epitope have an in vivo proliferative advantage. The data also provide an explanation for the conservation of this epitope
in exogenous FeLVs despite the existence of variant forms in enFeLV proviral elements with which they can recombine.
q 1995 Academic Press, Inc.
INTRODUCTION including a change in the sequence encoding a promi-
nent MGPNL pentapeptide which is highly conserved in
Of the three exogenous horizontally transmitted feline
the middle of the surface glycoprotein (SU) in exogenousleukemia virus (FeLV) subgroups A, B, and C (Sarma and
FeLVs (exFeLVs) and which represents a binding site forLog, 1971, 1973), FeLV-B viruses are clearly generated
a neutralizing monoclonal antibody, C11D8 (Elder et al.,from recombination of FeLV-A envelope (env) sequences
1987; Grant et al., 1983). In most rFeLVs, the portion ofwith the corresponding but varied endogenous FeLV (en-
the env gene backbone acquired during recombinationFeLV) proviral elements (Elder and Mullins, 1983; Kumar
contained the MGPNP sequence, not MGPNL, becauseet al., 1988; Overbaugh et al., 1988; Sheets et al., 1992,
the epitope is present as MGPNP in the endogenous1993; Stewart et al., 1986; Rohn et al., 1994). Previously
CFE-6 element.we obtained recombinant FeLVs (rFeLVs) by a process
Early epidemiological surveys reported that cats withof induced recombination between a molecular clone of
lymphosarcomas or leukemias had a higher incidenceFeLV-A/61E (Donahue et al., 1988) and env sequences
of harboring FeLV-B than asymptomatic FeLV-infectedfrom an enFeLV, CFE-6 (Soe et al., 1985), in transfected
animals (Jarrett et al., 1978). More recently, direct evi-cells (Sheets et al., 1992). The resultant recombinant vi-
dence based on molecular genetic analyses was ob-ruses, in which large portions of the FeLV-A env gene,
tained for the prevalence of FeLV-B-like viruses in natu-beginning from the 5* end, were replaced with se-
rally arising FeLV-related lymphosarcomas (Levy et al.,quences from the endogenous element, displayed poly-
1993; Sheets et al., 1993; Tsatsanis et al., 1994). Thus,tropic cell tropism similar to FeLV-B but different from the
it was of interest to examine the in vivo infectivity andecotropic nature of FeLV-A. Although in vitro replication
pathogenicity for a group of recombinants we previouslyproperties and overall sequence structure of the env
generated through recombination between FeLV-A andgene for these generated recombinants were very similar
enFeLV (Sheets et al., 1992). Additional impetus for theto FeLV-B (Kumar et al., 1989; Pandey et al., 1991; Sheets
study was derived from the observation that similar re-et al., 1992), there were scattered sequence variations,
combinants between FeLV-C and enFeLV could augment
the development of FeLV-C-related erythrocyte aplasia1 To whom correspondence and reprint requests should be ad-
dressed. in inoculated cats or alter in vivo tissue tropism (Mathes
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et al., 1994; Chakrabarti et al., 1994), as well as from the University, were inoculated intraperitoneally with 1125
FFU of cell-free virus prepared from cell culture fluid offinding that certain types of recombination could yield
FeLV env polyproteins defective in intracellular pro- rFeLV-infected HT1080 cells. The same virus preparation
was also used to inoculate three weanling (8- to 10-cessing and transport properties (Bechtel et al., 1994).
In the work described here, we present evidence that the week-old) SPF cats, which received the cell-free virus by
a combination of intravenous and intraperitoneal infec-FeLV-B-like recombinant viruses, analogous to certain
FeLV-B natural isolates, replicate and establish viremia tions. The older cats also received 10 mg/kg methylpred-
nisolone acetate in an attempt to facilitate the establish-in vivo only when administered in association with FeLV-
A, and coexist with FeLV-A as proviruses in these inocu- ment of viremia. In an attempt to mimic the natural condi-
tions of FeLV-B spread in cats, we next inoculated sixlated cats. Additionally, an intriguing possibility is indi-
cated by our finding that transition mutations at the neonates (4746-1 to 4746-6) with 4500 FFU of rFeLVs
along with 90 FFU of the uncloned FeLV-A/RickardMGPNP epitope altering the sequence to MGPNL may
be necessary to gain in vivo replication efficiency. This plasma preparation.
Blood samples were collected at biweekly intervalsfinding may explain why there is strict conservation of
the MGPNL epitope in exFeLVs despite the existence of postinoculation (pi) except the first interval, which was
omitted for the newborn groups due to their small size.variant forms in enFeLV proviral elements.
All inoculations and blood specimen collections were
performed under ketamine anesthesia (25 mg/kg). Hema-MATERIALS AND METHODS
tological parameters were determined at each sampling
Viruses interval at which time antigenemia and antibody re-
sponse were also measured. At necropsy, various tis-Recombinant FeLVs were previously produced by
sues were collected for histopathologic examinations,coexpression of a plasmid containing infectious mini-
molecular genetic analyses for provirus sequences, andmally pathogenic FeLV-A/61E (Donahue et al., 1988)
FeLV expression status.along with a plasmid containing different chimeric en-
Antigenemia was determined by a commercial ELISAFeLV constructs and were selected for their ability to
for the p27 capsid protein (Synbiotics Corp., San Diego,propagate in human cells resistant to infection by the
CA) in plasma. ELISA values were determined using anparental FeLV-A (Sheets et al., 1992). The recombinant
ELISA plate reader (Molecular Devices) at 650-nm wave-virus pool, previously designated A 1 r6env-LTR (Sheets
length; values were expressed as optical density andet al., 1992), now abbreviated and henceforth referred to
were not corrected for background. Negative and positiveas rFeLVs, was examined for in vivo biological properties.
controls included with each ELISA had values of 0.0387The rFeLVs contained multiple crossover sites in the env { 0.0042 and 0.421 { 0.119, respectively. The positivegene; major subpopulations previously identified in this
control had a calculated p27 protein content of 121pool were recombinants at A, B, E, F, and G sites. It
mg/ml.should be noted that the length of enFeLV env substitu-
The FeLV antibody response was measured by a live-tion at the 5* end of env increases from A to G and that
cell indirect immunofluorescence assay on the FL-74 fe-E to G sites reside downstream of the exFeLV MGPNL
line T-cell lymphoma cell line chronically infected withpentapeptide sequence (Sheets et al., 1992). Site D re-
FeLVs representing each of the A, B, and C subgroupssides within the epitope sequence. The recombinant vi-
(Essex et al., 1971; Mathes et al., 1994). Titers were ex-rus mixture was propagated in human fibrosarcoma
pressed as the reciprocal of serum dilution. Sera fromHT1080 cells (Pandey et al., 1991; Sheets et al., 1992)
uninfected SPF control cats gave titers of2. Each assayand virions released in culture supernatant fluids were
contained a positive control serum with a titer of 1024.monitored by enzyme-linked immunosorbent assay
Assays were discarded when the positive control serum(ELISA) for the virion p27 capsid protein. FeLV-A/Rickard
titer deviated more than one dilution from the expectedplasma inoculum was taken from a cat challenged at 9
value.weeks of age and collected at 14 weeks of age. This
challenge virus represented the eighth in vivo passage of
Tissue genomic DNA extraction and detectionFeLV-Rickard, which was originally derived from a tumor
of proviruseshomogenate and determined to be FeLV-A by direct inter-
ference assay. The titer of all infectious viruses was de-
Tissues from infected cats that had developed lympho-termined by the clone 81 S/L-focus induction assay of
sarcomas were snap frozen in liquid nitrogen immedi-Fischinger et al. (1974).
ately after removal from the animals following necropsy.
High-molecular-weight genomic DNA was extracted fromAnimal studies
tissues (tumor, bone marrow, lymph node, thymus,
spleen, and brain) using sodium dodecyl sulfate and pro-Four newborn, specific-pathogen-free (SPF) kittens, 1
to 2 days of age, from the breeding colony of Ohio State teinase K treatment followed by phenol–chloroform –
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isoamyl alcohol extraction as previously described vector (Invitrogen, San Diego, CA). White colonies were
screened for the full-length 1.5-kb insert by restriction(Sheets et al., 1993). A primer set, PRB-1 and PRB-2,
was used to specifically amplify recombinant env gene analyses, and positive clones were sequenced by di-
deoxy chain termination method (Sanger et al., 1980) assequences from the genomic DNA by polymerase chain
reaction (PCR) using a total of 40 cycles. Similarly, exoge- reported earlier (Pandey et al., 1991; Sheets et al., 1992).
The sequence for each of the recombinant env clonesnous FeLV-A-specific env sequences were amplified by
use of another primer set, RB-59 and PRB-2 (Sheets et was compared to those of parental CFE-6 enFeLV (Kumar
et al., 1989) and exogenous FeLV-A/61E (Donahue et al.,al., 1993). The resultant PCR products were run on agar-
ose gels and visualized by ethidium bromide staining. 1988).
Total RNA isolation from tissues and reverse RESULTS
transcription–polymerase chain reaction amplification
Infectivity and pathogenicity studies
Total RNA isolation from sera and tissue samples was
In the 3 weanling SPF cats and 4 neonatal SPF catsperformed using Clontech’s total RNA isolation kit (Palo
inoculated only with rFeLVs, none became viremic orAlto, CA), which employs a guanidinium isothiocyanate–
seroconverted up to 12 weeks of observation. Resultsphenol–chloroform extraction method (Chomczynski and
indicated that the recombinant viruses, like most naturalSacchi, 1987; Chirgwin et al., 1979). Reverse transcription
isolates of FeLV-B (Jarrett and Russell, 1978; Rojko et al.,(RT) reaction was performed using Moloney murine leu-
1979; Hoover et al., 1980), failed to induce viremia in anykemia virus reverse transcriptase (Gibco-BRL, Gaithers-
of the weanling age or newborn cats (data not shown).burg, MD) and oligo(dT) primer (Promega, Madison, WI)
In the 6 neonates inoculated with both FeLV-A/Rickardto synthesize cDNA. For each sample studied, 5 mg total
and rFeLVs, all 6 were antigenemic at the 4-week-pi sam-RNA was used in a 50-ml RT reaction. RT–PCR samples
pling point as determined by ELISA for viral capsid pro-without RNA or without reverse transcriptase enzyme
tein, and all had seroconverted as determined by live-were included in each experiment, serving as negative
cell indirect immunofluorescence assay (Table 1). Threecontrols. For detection of FeLV-A-specific fragments in
(4746-1, 4746-2, and 4746-5) developed thymic lympho-sera, 5 ml cDNA was used in the first round of amplifica-
sarcoma (LSA) and were euthanized to collect tumorstion employing the 5* primer RB59 and 3* primer RB52
and other tissues at 44, 75, and 90 weeks pi, respectively.(Sheets et al., 1993) in 35 PCR cycles. One microliter
One cat (4746-3) developed severe aplastic anemia andPCR product from the first round of amplification was
was euthanized at 37 weeks pi. The remaining 2 catsthen amplified in a second round of 35 amplification cy-
(4746-6 and 4746-4) developed cachexia and depressioncles using the nested primers 5* RB326 and 3* RB17
and were euthanized at 19 and 78 weeks pi, respectively.(Sheets et al., 1993), giving a 963-bp product. The RB326
From historic challenge studies of cats inoculated withprimer is oriented in the sense direction identical to posi-
only the FeLV-A/Rickard virus, 30 of 33 weanling cats,tions 6368 to 6391 of the published FeLV-A/61E strain
challenged at 8–10 weeks of age, developed chronic,sequence (Donahue et al., 1988). To detect the presence
life-long viremia. Of the chronically viremic cats observedof rFeLV fragments in sera, first-round amplification uti-
from 26 to 52 weeks pi, 2 of 19 developed lymphomas,lized 5* primer RB56 and 3* primer RB52 (Sheets et al.,
while 2 of 5 cats held greater than 52 weeks developed1993) in 35 PCR cycles. Second-round amplification em-
tumors.ployed the recombinant-specific nested primers RB53
(5*) and RB17 (3*) (Sheets et al., 1993) using 35 PCR
Detection of both FeLV-A and recombinant env genescycles and yielding an 888-bp fragment. First-round am-
in tissue DNA of cats with LSAplification using tissue cDNA utilized the same primers
as were employed with the sera samples. Second-round
The PCR strategy used to detect the presence and
amplification used RB326 (5*) and RB19 (3*) (Sheets et
type of env genes was similar to what was previously
al., 1993) for FeLV-A-specific expression, yielding a 1533-
described (Sheets et al., 1993). Specifically, rFeLV env
bp product. RB53 (5*) and RB19 (3*) primers were used
sequences were detected by PCR amplification in geno-
for rFeLV-specific expression, yielding a 1377-bp prod-
mic DNA extracted from tumor or other tissues of the
uct. PCR products from the second-round of amplification
infected cats using a primer specific for the 5* region of
were analyzed by 2% agarose gel electrophoresis and
enFeLV env gene, namely PRB-1, paired with a 3* primer
DNA bands visualized by ethidium bromide staining.
specific for FeLV-A env gene sequence (PRB-2). Similarly,
FeLV-A proviral env sequences were detected with aCloning and sequencing of PCR products
primer specific for 5* region of FeLV-A env (RB59) pairedfor rFeLV-specific env fragments
with the same 3* PRB-2 primer. PCR results for tissue
DNAs from one tumor-bearing cat are illustrated in Fig.PCR products generated from tissue DNA with the
PRB-1/PRB-2 primer set were cloned into the TA-cloning 1. Both FeLV-A and rFeLV env sequences were detected
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FIG. 1. Representative data of PCR analyses for tissue DNA isolated
from infected cats. (A) PCR products with rFeLV-specific primer set
(PRB-1 and PRB-2). After amplification of the tissue DNA (from cat 4746-
5), the products were resolved on gels and visualized by ethidium
bromide staining. DNA in lanes 1, bone marrow; 2, spleen; 3, brain; 4,
thymus; 5, lymph node; 6, lymphosarcoma; 7, positive control (A 1
r6env-LTR-infected HT1080 cells); 8, negative control (uninfected SPF
cat DNA); 9, water blank; and M, DNA markers. Arrow indicates position
of the approximately 1.5-kb band in marker which closely corresponds
to the expected band size from recombinant proviruses. The rFeLV-
specific primer set has previously been shown to not amplify FeLV-A
(Sheets et al., 1993). (B) PCR products with FeLV-A-specific primer set
(RB-59 and PRB-2). Similar analyses of the tissue DNAs as in A with
DNA in lanes 1–6, 8, 9, and M being the same as in A; 7, a positive
control (FeLV-A-infected feline H927 fibroblast cells). Arrow indicates
the position of 1.75-kb expected product. This FeLV-A-specific primer
set has been previously shown to not amplify pBHM1 (a FeLV-B plas-
mid) nor uninfected H927 cells (Sheets et al., 1993).
in the DNA of all the various tissues tested. Expected-
size PCR products, about 1.45 kb for recombinant env
and 1.75 kb for FeLV-A env (Sheets et al., 1993), were
generated. Similar results were obtained with tissues
from the other two cats in which LSA was induced (data
not shown). The presence of both FeLV-A and recombi-
nant proviruses in both tumor and normal tissue DNA
suggested that rFeLVs, like FeLV-B, could be infectious
in vivo when inoculated along with FeLV-A and they could
manifest broad tissue tropism.
Identification of crossover sites in the tissue
recombinant proviruses
PCR products generated to detect recombinant env
genes were cloned into the TA cloning vector and se-
quenced by priming with the M13 universal forward and
reverse primers as well as with oligonucleotides repre-
senting conserved sites internal to the insert. In a previ-
ous report several recombination points, A, B, E, F, and
G, were found to occur in clones of PCR products from
rFeLV-infected HT1080 cells (Sheets et al., 1992). How-
ever, this earlier study was limited since only eight clones
were examined, and the possibility remained that all po-
tential variants were not identified. In the present study
a larger number of clones were sequenced after amplifi-
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TABLE 2 Sheets et al., 1992). The sequence of this region was,
therefore, scrutinized for potential alterations in the re-Detection of Recombinant FeLV SU Sequences in Tissues
combinant species propagated in vivo. The finding wasof Infected Cats
striking. Of the 47 PCR clones sequenced, 41 showed
Total No. of a change in the deduced amino acid sequence of the
Cat Tissue clones Crossover site pentapeptide from MGPNP to MGPNL. The 6 clones with-
No. examined sequenced (in No. of clones)
out any change in amino acid sequence already con-
tained the MGPNL epitope because the site D recombi-4746-1 Tumor 8 D(1); D*(2); F(3); G(2)
Bone marrow 8 D(1); G(7) nation point is located upstream of the pentapeptide’s
4746-2 Tumor 7 D(3); F(2); G(2) C-terminal amino acid (i.e., P) encoded in the CFE-6 se-
Bone marrow 6 D(1); G(5) quence. These results, illustrated in Fig. 2, show that
4746-5 Tumor 6 G(6)
recombinants (site D*, site F, and site G) with crossoverBone marrow 6 G(6)
points downstream of the pentapeptide epitope exhibitedSpleen 6 G(6)
a C to T base change relative to enFeLV at the last
amino acid. This transition mutation is consistent with
conversion of the MGPNP to MGPNL sequence in allcation of tissue DNA from the infected cats. A total of 47
clones.clones were analyzed, representing two to three different
The issue that mutation happened in the backgroundtissues from the three LSA-positive cats. Those results
of parental CFE-6 sequence is further illustrated in Fig.are summarized in Table 2. Recombinant species with
3. Site F and site G recombinants were chosen to high-crossover sites at A, B, or E were not readily detected
light this point since they contain an extensive amountin the tissues. Although no definitive claim could be made
of enFeLV env substitution. While perfect homology wasbased upon PCR and cloning analyses, it appeared that
retained up to the crossover point in these two illustratedsome species with longer enFeLV env substitution (e.g.,
cases, MGPNP was invariably manifested as MGPNL.recombinants at sites F and G), could have in vivo replica-
Results were similar with other F and G recombinantstion advantage over other species such as A, B, or E
sequenced, except for one or two synonymous mutationsrecombinants. This, however, could not be the only crite-
in a few clones.rion for replication efficiency, since an intermediate spe-
cies (site D), which was apparently too minor a popula-
Detection of viral RNAs in sera and tissuestion in the inoculum to be detected, was readily observed
of infected catsin the tissues of two of the three cats. Additionally, a
variant site, located slightly downstream of site D, which
A representative experiment demonstrating the levelswe termed here as D*, was detected in one tumor DNA.
of FeLV viral RNA observed in sera from infected catOf all the recombinants, site G recombination type was
4746-5 is presented in Fig. 4. The top gel depicts thepresent in all tissues of the three cats examined in this
rFeLV-specific RNA pattern while the bottom showswork, and it appeared to be a primary, if not exclusive,
FeLV-A-specific RNA detected in the sera. FeLV-A viralcomponent in a single cat (4746-5) (Table 2). Since all
RNA was detected at the first collection time point, 4three tumor, bone marrow, and spleen tissues of this cat
weeks pi. Although the band was faint and not readilycontained this site G recombinant, at least in this animal
visible in this reproduction (bottom), repeated analysisthe site G recombinant species apparently had replica-
confirmed its presence at 4 weeks pi. The presence oftion advantage over other species.
FeLV-A viral RNA in the serum appeared to vary with
time since no band was present at 8 weeks pi, while atMutations detected in nucleotide sequence encoding
12 weeks pi a strong band was visible. This cyclicalthe enFeLV MGPNP pentapeptide
pattern for FeLV-A continued, with low levels detected at
16 to 24 weeks, followed by higher levels observed atAll sequenced exFeLVs are known to contain a
MGPNL pentapeptide epitope near the middle of SU. This 30 to 43 weeks pi. At the last collection time point of 44
weeks pi, a low FeLV-A level was again detected. Inpentapeptide, a binding site for a monoclonal antibody,
C11D8, was found to be varied (MGPNP or MGPDP) in contrast, rFeLV viral RNA levels shown in the top gel
(Fig. 4) indicated a relatively consistent pattern. A bandenFeLV loci present in cat DNA (Kumar et al., 1989;
Sheets et al., 1993) and expressed as env message in was first observed at 8 weeks pi, and the rFeLV viral
RNA level appeared to remain fairly uniform throughoutfeline lymphoid cells (McDougall et al., 1994). The site
D recombination point resides within this pentapeptide the 44-week time course. While this RT–PCR was not
quantitative per se, the analysis was designed to besequence, previously found to also be a frequent site of
mutation (Sheets et al., 1992, 1993). Alterations in this semiquantitative in that the total RNA for each serum
sample was standardized to 5 mg in the RT reaction andregion allowed escape from neutralization by the C11D8
monoclonal antibody (Nicolaisen-Strouss et al., 1987; the cDNA used in the PCR reaction was also equivalent
/ m4777$7637 11-21-95 01:55:20 vira AP-Virology
589RECOMBINANT FeLVS IN THYMIC LYMPHOSARCOMAS
FIG. 2. Presence of MGPNL sequence in all clones examined. Partial sequence encompassing the MGPNL pentapeptide epitope is shown for
each of the representative classes of recombinants with crossover sites at D, D*, F, and G which were detected in the tissues of the infected cats.
The nucleotide sequence alignment compares the sequence of parental FeLV-A/61E and enFeLV (CFE-6) with the recombinants in which variation
from 61E sequence is indicated in bold in all cases. Similarly, amino acid changes in relation to 61E are also shown in bold, while homology is
indicated by asterisks. Crossover site D falls within the pentapeptide region but sites F and G reside further downstream in the C-terminal half of
SU (Sheets et al., 1992). Site D*, first detected in this study, appears to be just a few nucleotides downstream of site D.
for each sample. This effort was intended to assure that
relative viral RNA levels were reflected for each serum
sample. In addition, the same cDNA preparations were
used in both sets of experiments depicted in Fig. 4. De-
tection of FeLV viral RNA in the FeLV-A/Rickard plasma
inoculum is also shown in Fig. 4. No rFeLV RNA was
FIG. 4. PCR detection of FeLV RNA levels in sera collected from catFIG. 3. Depiction of epitope sequence mutation in the background
of enFeLV homology. To illustrate this point, recombinants having 4746-5 from 4 to 44 weeks pi. At the top (rFeLV RNA) is depicted an
888-bp product from recombinant-specific nested PCR amplification.crossover points at sites F and G are presented due to their retention
of extensive enFeLV SU sequences and, thereby, increasing the power The gel on the bottom (FeLV-A RNA) shows a 963-bp product from
FeLV-A-specific nested PCR amplification. In both gels, the lanes con-of comparison. Nucleotide variations in FeLV-A/61E or the recombi-
nants (site F, site G) compared to the enFeLV CFE-6 are presented. tain the following samples reading from left to right: 4 weeks pi, RT(0);
4 weeks pi, RT(/); 8 weeks pi, 12, 16, 20, 24, 30, 38, 43, 44 weeks pi,The MGPNL or MGPNP region is shaded, and the difference in the
fifth amino acid between parental FeLV-A and enFeLV is indicated. and 44 weeks pi, RT(0); respectively. The lack of a band in the lane
containing the FeLV-A/Rickard plasma inoculum demonstrates theseNucleotide residues identical to CFE-6 are indicated by ( . ) and dele-
tions by (- ). The position of recombination site F is marked by a bar are recombinant-specific primers. Recombinant FeLV (rFeLV) cDNA
served as positive control, followed by uninfected feline H927 cDNAabove the sequence and that of site G by a bar below the sequence.
The SU gene sequence, beginning from the top left and ending at the as negative control, water, and 100-bp DNA ladder, respectively. At the
bottom (FeLV-A RNA), the positive control is FeLV-A/61E. All other lanesbottom right, represents published sequence number 6662–6889 of
61E (Donahue et al., 1988) and number 770–1030 of CFE-6 (Kumar et in the bottom gel contain the same samples in the order described for
the top.al., 1989).
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detected in the plasma inoculum (top), while a strong FeLV-A used in the generation of our recombinants, indi-
cate a low frequency of thymic tumor induction (4 ofFeLV-A-specific band was observed in this inoculum
(bottom). 28 cats) as previously reported (Overbaugh et al., 1992;
Quackenbush et al., 1990; Rohn et al., 1994). Although aFeLV-A expression was detected in cDNA from all tis-
sues evaluated from four FeLV-infected cats, including larger study, as well as a parallel control study including
FeLV-A alone, will be necessary to define the signifi-the three LSA-positive cats (4746-1, 4746-2, and 4746-5)
as well as the cat diagnosed with aplastic anemia (4746- cance of rFeLVs in lymphomagenesis, at present there is
an indication that the presence of rFeLVs may potentiate3) (data not shown). The tissues analyzed for FeLV ex-
pression were tumor, lymph node, spleen, bone marrow, malignancy development.
While analyzing tissue DNAs obtained from tumor-thymus, and brain. Recombinant-specific FeLV expres-
sion was also detected in all tissue cDNA samples from bearing cats, it was of much interest to find the presence
of the MGPNL epitope sequence, and not the expectedthe four FeLV-infected cats with one notable exception.
No rFeLV expression was detected in the bone marrow of enFeLV-encoded MGPNP sequence of the CFE-6 recom-
bination partner, in the recombinant proviruses dis-the aplastic anemia-diagnosed cat, 4746-3, even though
FeLV-A expression was detected in this cat’s bone mar- playing recombination points downstream of the epitope
(e.g., D*, F, and G sites). So far all exFeLV molecularrow cDNA (data not shown).
clones sequenced, including four FeLV-As, one FeLV-C,
and three FeLV-Bs, have been found to contain theDISCUSSION
MGPNL pentapeptide in the middle of the SU glycopro-
tein (Neil et al., 1991). In contrast, two enFeLV provirusFeLV-A is seen in all natural infections and its pres-
ence is required for the in vivo infectivity of FeLV-B or clones or enFeLV cDNA clones examined reveal a variant
sequence of MGPNP or MGPDP in this region (Kumar etFeLV-C (Jarrett et al., 1978; Jarrett and Russell, 1978;
Sarma et al., 1978). In studies with molecularly cloned al., 1989; McDougall et al., 1994; Neil et al., 1991; Sheets
et al., 1993). Thus, in consideration of the origin of FeLV-FeLV-B or FeLV-C, FeLV-B/Gardner–Arnstein strain fails
to induce viremia in weanling age or newborn cats even B viruses from enFeLV elements, it has been difficult
to explain the retention of MGPNL epitope in FeLV-Bin the presence of corticosteroids (Rojko et al., 1979;
Hoover et al., 1980), and FeLV-C/Sarma strain, while ca- subgroup isolates. Now, however, our data suggest that
in vivo reversion of the epitope may be responsible forpable of infecting newborn cats, fails to induce viremia
in animals beyond 1 week of age (Reidel et al., 1986). these observations. In the midst of perfect homology to
the CFE-6 substituted region, its MGPNP sequence isThe lack of in vivo infectivity we observed with our rFeLVs
generated by in vitro recombination, and which exhibited converted to MGPNL as deduced from a C to T transition
in the codon of the fifth amino acid. Apparently this hasgenetic similarity to FeLV-B, is consistent with the nature
of FeLV-B infectivity. Similarly, we demonstrate that effi- happened to all recombinant virus clones examined in
each of the three LSA-positive cats studied. Additionally,cient in vivo proliferation of rFeLVs can be achieved only
in the presence of FeLV-A helper virus. These results, the coexistence of FeLV-A seems to be required for the
observed changes, since in another study, when new-taken together with earlier findings of genetic make-up
and expanded in vitro cell tropism of such recombinants born cats were inoculated with another subpopulation of
rFeLVs alone (prepared in vitro by selection of neutraliza-(Overbaugh et al., 1988; Pandey et al., 1991; Sheets et
al., 1992) further corroborate the conclusion that FeLV-B tion resistance to C11D8 monoclonal antibody), none of
the cats developed viremia or seroconverted (our unpub-viruses arise in nature through genetic recombination
between enFeLV and exogenous FeLV-A. lished data). However, recombinant proviruses could be
detected by PCR in the bone marrow of these cats 45There is evidence that FeLV-B viruses are associated
with leukemogenesis (Hardy, 1990; Jarrett and Russell, weeks pi, and sequencing of the PCR clones revealed
unchanged MGPNP sequence consistent with the rest1978; Tzavaras et al., 1990; Sheets et al., 1993; Tsatsanis
et al., 1994; Rohn et al., 1994). In the current study, 3 of of the portion of enFeLV (CFE-6) sequence. Thus, efficient
in vivo replication of the rFeLVs in the presence of FeLV-6 cats, infected with rFeLVs along with FeLV-A/Rickard,
developed detectable thymic lymphosarcomas within a A may be a requisite for epitope reversion, potentially
due to either point mutations from increased cycles ofperiod ranging from 40 to 86 weeks postinoculation. In
another investigation, 2 of 19 cats inoculated only with replication or recombination with FeLV-A around the epi-
tope region, followed by in vivo selection for their growththe helper FeLV-A/Rickard virus inoculum and kept under
study for up to 52 weeks pi presented with lymphomas advantage.
Although the above scenario seems to us the most(data not shown). Although these control experiments
were parts of other studies, a few of the cats were also likely explanation, other reasons for the observations
cannot be excluded. For example, recombinant virusesobserved for longer than 52 weeks. Two of 5 such cats
exhibited hematopoietic malignancies (data not shown). which we detected in the cats might be different, newly
generated recombinants formed in vivo through recombi-In vivo studies with cloned FeLV-A/61E, the parental
/ m4777$7637 11-21-95 01:55:20 vira AP-Virology
591RECOMBINANT FeLVS IN THYMIC LYMPHOSARCOMAS
nation of FeLV-A with enFeLV elements. If any of the recognition, membrane insertion, membrane fusion, and
virus maturation. The factors that regulate these interac-multiple of the enFeLV loci retained the MGPNL se-
quence and was indeed a partner in recombination, it tions may more likely be encountered under in vivo condi-
tions than under in vitro cell culture conditions wheremight be difficult to distinguish a newly formed recombi-
nant from the potentially homologous CFE-6 sequence. pentapeptide changes may have little significant effect
on virus replication efficiency. In addition to the observedThis possibility is at least partly deemphasized by our
finding that the FeLV-A/Rickard plasma inoculum did not epitope reversion, it is also demonstrated here that rFeLV
replication efficiency in vivo may also be dictated by thecontain any detectable recombinant viruses. Another
possibility may be that viruses detected in the cat were site of recombination. Some rFeLV species appear to
have an in vivo proliferative advantage. One such recom-actually present in the rFeLV pool and then outgrew oth-
ers in vivo without any induced changes in the epitope binant, site G rFeLV, detected in all three tumor-bearing
cats, could potentially represent an example of replica-region. This, however, does not affect our proposition that
recombinant viruses with MGPNL epitope are indeed tion efficiency coupled to a strong leukemogenic func-
tion.products of recombination between enFeLV and FeLV-A
but with subsequent mutation in the epitope area (Sheets
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